Navigation Links
Peregrine Pharmaceuticals to Announce Third Quarter FY 2008 Financial Results
Date:3/4/2008

TUSTIN, Calif., March 4 /PRNewswire-FirstCall/ -- Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM), a clinical stage biopharmaceutical company developing monoclonal antibodies for the treatment of cancer and hepatitis C virus (HCV) infection, today announced that it will release its financial results for the third quarter of fiscal year 2008 on March 11, 2008 at 7:00 a.m. EDT and will host a conference call and webcast to discuss the results at 11:30 a.m. EDT on the same day.

Peregrine's senior management will discuss financial results for the quarter and will review recent operating highlights. A question-and-answer session will follow management's discussion. All interested parties are encouraged to listen to the live conference call or the live or archived webcast.

The conference call and webcast will begin at 11:30 a.m. EDT/8:30 a.m. PDT.

To listen to a live broadcast of the call over the Internet or to review the archived webcast, please visit: http://www.peregrineinc.com. The webcast will be archived on Peregrine's website for 30 days.

To listen to the conference call via telephone, please call the following number approximately 10 minutes prior to the scheduled start time and request to join the Peregrine Pharmaceuticals call: 1 (800) 860-2442. A telephonic replay of the conference call will be available starting approximately one hour after the conclusion of the call through March 18, 2008 by calling (877) 344-7529, passcode 382933#.

About Peregrine Pharmaceuticals

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of innovative product candidates in clinical trials for the treatment of cancer and hepatitis
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. Publication in Clinical Cancer Research Confirms Ability of Peregrines Bavituximab to Target Tumor Blood Vessels with Excellent Specificity
2. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
3. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
4. Peregrine Pharmaceuticals Remains on Track to Advance its Three Lead Clinical Programs in 2008
5. Defense Threat Reduction Agency Halts Contract Negotiations With Peregrine Pharmaceuticals as It Suffers $100 Million Cut in FY 2008 Budget for Its Transformational Medical Technologies Initiative (TMTI) Program
6. Peregrine Pharmaceuticals to Announce Second Quarter FY 2008 Financial Results
7. New Data Presented on Immunocytokine Fusion Protein Further Supports Broad Anti-Cancer Potential Of Peregrines Anti-PS Technology Platform
8. Peregrine Pharmaceuticals to Announce First Quarter FY 2008 Financial Results
9. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
10. MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
11. SGX Pharmaceuticals Schedules Teleconference and Webcast for Fourth Quarter and Full Year 2007 Results

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/24/2009)... Ambassador to also Visit Detroit , ...o: David Appia, French Ambassador for Internationa...n France Agency, , , , ,What: Ambassador Appia is...o-business initiatives adopted by France to furthe...cape for innovation and development., , ,When: Ava...
(Date:11/24/2009)...d BLENHEIM, Ontario, Nov. 24 /PRNewswire-FirstCall... acquiring the assets of Hyland Seeds, a division ...ition of Hyland Seeds will further expand Dow Agro...ticipates the introduction of SmartStax(TM) in ...ait Technology in corn in 2012. The transactional ...
(Date:11/24/2009)... Health care employment grew by 29,000 jobs i...how consistent growth during the U.S. recession. H...trouble, and health systems are coming closer to h...f just administrators. , ...t continued growing in October despite the sheddin...
(Date:11/24/2009)...TEO, Calif., Nov. 24 Neu... company focused on developing and commercializing...that Anthony DiTonno, President and Chief Executiv...ual Piper Jaffray Health Care Conference, to be he... in New York, New York. ,, Mr. DiTonno and Ste...
Breaking Biology Technology:Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 2Dow AgroSciences Canada Announces Agreement to Acquire Hyland Seeds 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 2The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 3The MedZilla Report for October 2009 - Health Care Employment Grows Again in October Even As Clinics, Specialty Centers Close 4NeurogesX to Present at Piper Jaffray Health Care Conference 2NeurogesX to Present at Piper Jaffray Health Care Conference 3
... operating expenses decreased by 33% in 2008; Fore...ly 50% in 2009 , , CTI expects to complete pixan...ch 16 Cell Therapeutics, Inc. (CTI) (Nasdaq and M...d financial results for the fourth quarter and yea..., , Met primary endpoint in the Phase II...
... Med Discovery SA, a speciali...s proud to announce that they have extended their ...ma, a subsidiary of Validapro BioSciences Inc. to ... clinical manufacturing of all molecules under dev... (PRWEB) March 14, 2009 -- Med Discovery SA, a ...
...TTLE, March 13 /PRNewswire-FirstCall/ - Oncothyreo...y company specializing in the development of innov...ncer, today announced that Robert Kirkman, M.D., P... at the Invest Northwest 2009 Conference at 9:40 a... live and archived webcast of Dr. Kirkman,s presen...
Other Biology Technology:Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 2Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 3Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 4Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 5Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 6Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 7Cell Therapeutics, Inc. (CTI) Reports 2008 Fourth Quarter and Year End Financial Results 8Med Discovery and Laborium Biopharma Extend Their Development Partnership to Include Mammalian Cell Culture Processes and Clinical Manufacturing for All Products in Med Discovery's Portfolio 2
(Date:11/24/2009)...-- The Wildlife Conservation Society (WCS) announc...g population of Siberian tigers has likely decline... and habitat loss. , WCS says the re...eds to be done to protect remaining populations of...ort was released by the Siberian Tiger Monitoring ...
(Date:11/24/2009)...rch on bacterial communities throughout six large ...al patterns, suggesting that scientists could use ...e change in the polar regions. The study, publishe...ademy of Sciences Early Edition, shows that bacte...nously over time, correlating with seasonal shifts...
(Date:11/23/2009)...rain of the deadly superbug MRSAan infection-causi...ses a far greater health threat than previously kn...g to a study in the December issue of Emerging In...picked up in fitness centers, schools, and other p...of MRSA within hospitals, the report found. , Th...
Breaking Biology News(10 mins):Report shows dramatic decline in Siberian tigers 2Researchers establish common seasonal pattern among bacterial communities in Arctic rivers 2New study finds MRSA on the rise in hospital outpatients 2Cord Blood America Announces Preferred Pricing for Blue Cross of Northeastern Pennsylvania Members 13602 1Cord Blood America Announces Preferred Pricing for Blue Cross of Northeastern Pennsylvania Members 13602 2Free Online Tools Benefitting Time Starved Cost Conscious Home Cooks 54709 1Free Online Tools Benefitting Time Starved Cost Conscious Home Cooks 54709 2Biosciences Firm Chooses CloudCraze for eCommerce Business Solution LI COR and EDL Consulting Take Expertise into the 26quot 3BCloud 26quot 3B 13600 1Biosciences Firm Chooses CloudCraze for eCommerce Business Solution LI COR and EDL Consulting Take Expertise into the 26quot 3BCloud 26quot 3B 13600 2Biosciences Firm Chooses CloudCraze for eCommerce Business Solution LI COR and EDL Consulting Take Expertise into the 26quot 3BCloud 26quot 3B 13600 3
... human looks at a number, letter or other shape, n...er respond to different components of that shape, ...a puzzle to create an image that the individual th...s Hopkins University report. , A team from the uni...ribes the complex but speedy process in detail in ...
...ns, one of the basic components of living things, ...ry. Understanding how proteins form or "fold" from...e of the grand challenges of biology. , A common ...y their environment, the more stable - or less lik...he cover of the March issue of Biophysical Journal...
...r: Yeah, I hate it too when there,s no picture in ...ture of a molecule that plays a key role in activa... been obtained by researchers at the European Mole...e Virologie Moléculaire et Structurale (IVMS), ass... CNRS, in Grenoble. , Like Sleeping Beauty, the Ep...
Other Biology News:In the mind's eye: How the brain makes a whole out of parts 2UW-Madison engineers squeeze secrets from proteins 2Waking a sleeping virus 2
...vations of cell cultures under precise, controlled...nt strain parameters in addition to a microscope m...amber used by the ST-195 is compatible with invert... can be used with Nikon, Olympus, Leica, and Zeiss...
Rabbit Anti-JNK3 / SAPK1b Monoclonal Antibody, Unconjugated, Clone C05T from Upstate
...ction with the EasyCount System to count dead and ...taining Reagent uses a mixture of ready-to-use nuc...ide to identify live and dead cells, respectively,...lti-well Slide provides the ability to perform up ...
...rful yet simple technology for labeling peptides, ...t provides the heterobifunctional linkers SFB and ...on efficiencies. It enables conjugation of various...other tags with a variety of proteins. , The che...
Biology Products: